RxDoctor Payments Data

Jeffrey Akhtar, DO

Internal Medicine · Charleston, SCNPI 1053370841

Payments from drug & device makers

$10,049in general payments, 2019–2025

Across 530 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$904
  • GSK$902
  • Novo Nordisk$877
  • Bayer$706
  • Amarin Pharma, Inc.$655
  • Johnson & Johnson$633
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,032100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC58$904
GSK42$902
Novo Nordisk62$877
Bayer37$706
Amarin Pharma, Inc.32$655
Johnson & Johnson20$633
AbbVie(2 entities)36$587
Pfizer35$579
AstraZeneca25$569
Abbott18$307
Amgen15$287
Boehringer Ingelheim10$216
Biohaven Pharmaceutical Holding Company Ltd.4$177
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$159
Takeda Pharmaceuticals U.S.A., Inc.8$145
Novartis8$136
Eisai Inc.9$132
Kowa Pharmaceuticals America, Inc.7$127
Gilead1$125
Esperion Therapeutics, Inc.7$110
Axsome Therapeutics, Inc.4$103
Exact Sciences4$89
Arbor Pharmaceuticals, Inc.6$87
Sanofi-aventis U.S. LLC5$85
Astellas Pharma US Inc4$79
Cequr Corporation1$77
Mylan Specialty L.p.5$76
E.r. Squibb & Sons, L.L.C.4$74
Boston Scientific4$73
Merck4$64
Xeris Pharmaceuticals, Inc.3$61
Shire North American Group Inc3$52
Edwards Lifesciences1$48
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$47
Organogenesis Inc.2$46
Endo Pharmaceuticals Inc.3$44
Phathom Pharmaceuticals, Inc.2$42
Lundbeck LLC2$41
Almatica Pharma LLC2$40
Sumitomo Pharma America, Inc.2$33
Otsuka America Pharmaceutical, Inc.2$32
Sanofi Pasteur Inc.2$30
Phadia US Inc.1$30
Kyowa Kirin, Inc.1$25
Dova Pharmaceuticals1$25
Biohaven Pharmaceuticals, Inc.1$25
Sunovion Pharmaceuticals Inc.2$24
Forte Bio-pharma LLC2$24
Sandoz1$22
Corcept Therapeutics1$21
Collegium Pharmaceutical, Inc.1$20
Inspire Medical Systems, Inc.1$18
Nabriva Therapeutics, PLC1$18
Paratek Pharmaceuticals, Inc.1$17
Medtronic1$16
Dermira, Inc.1$16
Scilex Pharmaceuticals Inc.1$15
Idorsia Pharmaceuticals US Inc1$14
Avanir Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,049 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$66,361
Medicare patients
118
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$73,656
EliquisApixaban54$54,432
VascepaIcosapent Ethyl54$42,134
MounjaroTirzepatide32$37,358
JanuviaSitagliptin Phosphate23$29,961
RybelsusSemaglutide24$26,365
FarxigaDapagliflozin Propanediol14$19,388
Humalog Kwikpen U-200Insulin Lispro28$19,052
XareltoRivaroxaban26$18,659
TrulicityDulaglutide11$15,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,802
Icosapent Ethyl53$12,987
LinzessLinaclotide16$8,643
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,567
OxycontinOxycodone Hcl11$6,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$877$100,02291 claims
PfizerEliquis$579$54,43254 claims
Lilly USA, LLCMounjaro, Trulicity$904$53,05943 claims
MerckJanuvia$64$29,96123 claims
AstraZenecaFarxiga, Breztri Aerosphere$569$26,95526 claims
Johnson & JohnsonXarelto$633$18,65926 claims
GSKTrelegy Ellipta$902$14,80216 claims
AbbVieLinzess$587$8,64316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →